John R. Cashman

John R. Cashman is the Chief Executive Officer and has more than 30 years of experience in biomedical research as a researcher, consultant, entrepreneur, or administrator. In 1997, he founded the Human BioMolecular Research Institute, a non-profit research institute dedicated to conducting fundamental and applied research to address important human diseases of the central nervous system. Previously, he was a Senior Scientist at the Seattle Biomedical Research Institute, and prior to that, he was Associate Director for the IGEN Research Institute in Seattle, Washington. In 1984, he was appointed Assistant Professor of Chemistry and Pharmaceutical Chemistry at the University of California, San Francisco. He completed a postdoctoral fellowship in the Department of Chemistry at Harvard University in Cambridge, Massachusetts with Professor E.J. Corey (1982-1984). In 1990, Professor Corey received the Nobel Prize. Dr. Cashman received his Master's and doctorate degrees in Medicinal Chemistry from the University of Kansas, Lawrence, Kansas (1982). Prior to graduate school, he obtained bachelor's degrees in chemistry and biology at the College of Creative Studies, University of California, Santa Barbara (1977). Dr. Cashman was a University of California Presidents Undergraduate Researcher (1974-1976), received a Sigma Xi Undergraduate Research Fellowship (1975), was a PEW Scholar Nominee at the University of California, San Francisco (1986), received a March of Dimes Basil O’Connor Research Award (1986), was appointed Technical Advisor, San Francisco Estuary Project (1990) and was elected Fellow of the American Association for the Advancement of Science in 1996. In 1991, Dr. Cashman was appointed to the Editorial Advisory Board, of Chemical Research in Toxicology, and in 1999 he was appointed to the Editorial Advisory Board of Current Drug Metabolism. Dr. Cashman is the author of over 220 research articles or book chapters and 16 patents in the area of drug discovery and evaluation. He is extensively consulted by biotechnology, the pharmaceutical industry, and the government in various areas of human drug development, drug safety evaluation, medicinal chemistry, pharmacogenetics, and biochemical Toxicol